Related references
Note: Only part of the references are listed.Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas
Benjamin M. Ellingson et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab
Benjamin M. Ellingson et al.
NEURO-ONCOLOGY (2011)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Validation of Functional Diffusion Maps (fDMs) as a Biomarker for Human Glioma Cellularity
Benjamin M. Ellingson et al.
JOURNAL OF MAGNETIC RESONANCE IMAGING (2010)
A Vascular Normalization Index as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients
A. Gregory Sorensen et al.
CANCER RESEARCH (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan
R. M. Zuniga et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
The parametric response map is an imaging biomarker for early cancer treatment outcome
Craig J. Galban et al.
NATURE MEDICINE (2009)
Bevacizumab and chemotherapy for recurrent glioblastoma A single-institution experience
P. L. Nghiemphu et al.
NEUROLOGY (2009)
Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
F. M. Iwamoto et al.
NEUROLOGY (2009)
Recurrent Glioblastoma Multiforme: ADC Histogram Analysis Predicts Response to Bevacizumab Treatment
Whitney B. Pope et al.
RADIOLOGY (2009)
Voxel-based assessment of differences in damage and distribution of white matter lesions between patients with primary progressive and relapsing-remitting multiple sclerosis
Carol Di Perri et al.
ARCHIVES OF NEUROLOGY (2008)
Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors
Felix Bokstein et al.
CANCER (2008)
Functional diffusion map as an early imaging biomarker for high-grade glioma: Correlation with conventional radiologic response and overall survival
Daniel A. Hamstra et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Time course of imaging changes of GBM during extended bevacizumab treatment
Suchitra Ananthnarayan et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
High-grade glioma before and after treatment with radiation and Avastin: Initial observations
Ingeborg Fischer et al.
NEURO-ONCOLOGY (2008)
Bevacizumab for recurrent malignant gliomas - Efficacy, toxicity, and patterns of recurrence
A. D. Norden et al.
NEUROLOGY (2008)
Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography:: A pilot study
Wei Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects
Dan G. Duda et al.
TRENDS IN MOLECULAR MEDICINE (2007)
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
James J. Vredenburgh et al.
CLINICAL CANCER RESEARCH (2007)
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
WB Pope et al.
NEUROLOGY (2006)
Expression of VEGF and its receptors in different brain tumors
HG Huang et al.
NEUROLOGICAL RESEARCH (2005)
Functional diffusion map: A noninvasive MR1 biomarker for early stratification of clinical brain tumor response
BA Moffat et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Diagnostic value of the fast-FLAIR sequence in MR imaging of intracranial tumors
HW Husstedt et al.
EUROPEAN RADIOLOGY (2000)
Share Paper
